HCM Q2 2023 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$266M+31.9% YoY

Gross Profit

$162M60.9% margin

Operating Income

$56M21.0% margin

Net Income

$84M31.6% margin

EPS (Diluted)

$0.49

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

$113M

Free Cash Flow

$101M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$497M

Stockholders' Equity

$782M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$266M	$202M	+31.9%
Gross Profit	$162M	$65M	+150.7%
Operating Income	$56M	-$197M	+128.4%
Net Income	$84M	-$163M	+151.7%

Revenue Segments

Other Collaboration Licensing Revenue

$250M78%

Collaboration Research And Development

$29M9%

Commercialization Services

$25M8%

Other Collaboration Royalties Revenue

$15M5%

Seroquel

$1M0%

Research And Development Services

$246,0000%